Risk factors and mortality outcomes of COVID-19 in people living with HIV: a systematic review and meta-analysis.

IF 1.9 4区 医学 Q4 IMMUNOLOGY
Mahmoud Kandeel
{"title":"Risk factors and mortality outcomes of COVID-19 in people living with HIV: a systematic review and meta-analysis.","authors":"Mahmoud Kandeel","doi":"10.24875/AIDSRev.23000017","DOIUrl":null,"url":null,"abstract":"<p><p>This study was performed to reveal the risk factors associated with mortality in people living with HIV (PLHIV) who were diagnosed with COVID-19. Studies reporting deaths among PLHIV and infected with SARS-CoV-2 were investigated. After protocol setup and registration, the extracted sources were categorized and assessed for quality. This study examined ten articles with a total of 46,136 patients. Patients aged ≥ 60 years (hazard ratio [HR] = 2.22; 95% CI: 1.617, 3.050; p < 0.001), male (HR = 1.668; 95% CI: 1.179, 2.361; p = 0.004), and people with diabetes (risk ratio [RR] = 3.34; 95% CI: 1.45, 7.68; p = 0.005) were at higher risk of death. Adherence to antiretroviral therapy (ART) reduced mortality risk (RR = 0.90; 95% CI: 0.83, 0.98; p = 0.02). Patients in the survival groups showed a statistically significant lower mean of C-reactive protein (mean difference = 114.08; 95% -74.05, 154.10; p < 0.001). Deceased patients showed higher mean levels of interleukin-6 (IL-6). Chronic respiratory disorders, hypertension, oxygen requirement, admission to an intensive care unit, D-dimer levels, and HIV viral load < 50 copies RNA/mL before admission did not show statistically significant differences between the deceased and survival groups. ART therapy reduced mortality risk (RR = 0.90; 95% 0.83, 0.98; p = 0.02). Identifying PLHIV at higher mortality risk could improve the outcomes of COVID-19 by stratifying these patients to the most effective treatment in a timely fashion.</p>","PeriodicalId":7685,"journal":{"name":"AIDS reviews","volume":"26 1","pages":"1-14"},"PeriodicalIF":1.9000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIDS reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.24875/AIDSRev.23000017","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

This study was performed to reveal the risk factors associated with mortality in people living with HIV (PLHIV) who were diagnosed with COVID-19. Studies reporting deaths among PLHIV and infected with SARS-CoV-2 were investigated. After protocol setup and registration, the extracted sources were categorized and assessed for quality. This study examined ten articles with a total of 46,136 patients. Patients aged ≥ 60 years (hazard ratio [HR] = 2.22; 95% CI: 1.617, 3.050; p < 0.001), male (HR = 1.668; 95% CI: 1.179, 2.361; p = 0.004), and people with diabetes (risk ratio [RR] = 3.34; 95% CI: 1.45, 7.68; p = 0.005) were at higher risk of death. Adherence to antiretroviral therapy (ART) reduced mortality risk (RR = 0.90; 95% CI: 0.83, 0.98; p = 0.02). Patients in the survival groups showed a statistically significant lower mean of C-reactive protein (mean difference = 114.08; 95% -74.05, 154.10; p < 0.001). Deceased patients showed higher mean levels of interleukin-6 (IL-6). Chronic respiratory disorders, hypertension, oxygen requirement, admission to an intensive care unit, D-dimer levels, and HIV viral load < 50 copies RNA/mL before admission did not show statistically significant differences between the deceased and survival groups. ART therapy reduced mortality risk (RR = 0.90; 95% 0.83, 0.98; p = 0.02). Identifying PLHIV at higher mortality risk could improve the outcomes of COVID-19 by stratifying these patients to the most effective treatment in a timely fashion.

艾滋病毒感染者中 COVID-19 的风险因素和死亡结果:系统回顾和荟萃分析。
本研究旨在揭示与确诊感染 COVID-19 的艾滋病病毒感染者(PLHIV)死亡相关的风险因素。研究调查了报告感染 SARS-CoV-2 的艾滋病毒携带者和艾滋病患者死亡的研究。在设定和登记研究方案后,对提取的资料进行了分类和质量评估。本研究共研究了 10 篇文章,涉及 46,136 名患者。年龄≥60岁(危险比 [HR] = 2.22;95% CI:1.617, 3.050;p < 0.001)、男性(HR = 1.668;95% CI:1.179, 2.361;p = 0.004)和糖尿病患者(危险比 [RR] = 3.34;95% CI:1.45, 7.68;p = 0.005)的死亡风险较高。坚持抗逆转录病毒疗法(ART)可降低死亡风险(RR = 0.90; 95% CI: 0.83, 0.98; p = 0.02)。存活组患者的 C 反应蛋白平均值明显降低(平均差异 = 114.08;95% -74.05,154.10;P <0.001)。死亡患者的白细胞介素-6(IL-6)平均水平较高。慢性呼吸系统疾病、高血压、氧气需求、入住重症监护室、D-二聚体水平以及入院前艾滋病毒病毒载量< 50 copies RNA/mL在死亡组和存活组之间没有统计学意义上的差异。抗逆转录病毒疗法降低了死亡风险(RR = 0.90; 95% 0.83, 0.98; p = 0.02)。识别死亡风险较高的艾滋病毒感染者可以改善 COVID-19 的治疗效果,及时对这些患者进行分层,使其接受最有效的治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
AIDS reviews
AIDS reviews 医学-传染病学
CiteScore
3.40
自引率
4.50%
发文量
41
审稿时长
>12 weeks
期刊介绍: AIDS Reviews publishes papers reporting original scientific, clinical, epidemiologic and social research which contribute to the overall knowledge of the field of the acquired immunodeficiency syndrome and human retrovirology. Currently, the Journal publishes review articles (usually by invitation, but spontaneous submitted articles will also be considered). Manuscripts submitted to AIDS Reviews will be accepted on the understanding that the authors have not submitted the paper to another journal or published the material elsewhere.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信